July 25, 2017 11:39 AM ET

Pharmaceuticals

Company Overview of Daiichi Sankyo Europe GmbH

Company Overview

Daiichi Sankyo Europe GmbH develops, manufactures, and markets pharmaceutical products for hypertension, dyslipidemia, bacterial infections, and thrombotic disorders. The company also provides products for cardiovascular and thromboembolic diseases, as well as antiplatelet agents. Its products include LIXIANA for anticoagulation; Efient for acute coronary syndrome requiring percutaneous coronary intervention; and Olmetec, Olmetec Plus, Sevikar, and Sevikar HCT for essential hypertension. The company offers its products in Germany and internationally. Daiichi Sankyo Europe GmbH was formerly known as Sankyo Pharma GmbH and changed its name to Daiichi Sankyo Europe GmbH in July 2006. The compan...

Zielstattstrasse 48

Munich,  81379

Germany

Founded in 1910

Phone:

49 089 78 080

Fax:

49 89 7808267

Key Executives for Daiichi Sankyo Europe GmbH

Chairman of the Board, Chief Executive Officer and Managing Director
Age: 58
Chief Financial Officer
Age: 52
CEO & MD of Daiichi Sankyo Austria, CEO & MD of Deutschland and CEO & MD of (Schweiz) AG
Age: 52
President of Daiichi Sankyo France SAS
Head of Media Relations
Compensation as of Fiscal Year 2017.

Daiichi Sankyo Europe GmbH Key Developments

Daiichi Sankyo Europe GmbH Initiates ENVISAGE-TAVI AF Study Investigating

Daiichi Sankyo Europe GmbH announced that the first patient has been enrolled into the ENVISAGE-TAVI AF study. The multinational, randomised phase 3b study will evaluate a treatment regimen based on the company's oral, once-daily direct factor Xa-inhibitor edoxaban (known by the brand name LIXIANA outside the US and SAVAYSA in the US) against a vitamin K antagonist based regimen, with or without antiplatelet therapy, in patients with atrial fibrillation (AF) following successful transcatheter aortic valve implantation (TAVI). The study will investigate the incidence of net adverse clinical events (NACE), including the composite of all-cause death, myocardial infarction (MI), ischaemic stroke, systemic thromboembolism (SEE), valve thrombosis, and major bleeding (International Society on Thrombosis and Haemostasis [ISTH] definition). Approximately 1,400 patients will be enrolled in ENVISAGE-TAVI AF from 200 clinical sites across Europe, the United States and Canada.

Daiichi Sankyo Europe GmbH Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 10:30 AM

Daiichi Sankyo Europe GmbH Presents at The 14th Annual BIO Asia International Conference, Mar-15-2017 10:30 AM. Venue: Grand Hyatt Tokyo, Tokyo, Japan.

Daiichi Sankyo Europe GmbH Announces Initiation of Real-World Study in LIXIANA (Edoxaban) Patients Undergoing Diagnostic and Therapeutic Procedures in Non-Valvular Atrial Fibrillation and Venous Thromboembolism

Daiichi Sankyo Europe GmbH (Daiichi Sankyo) announced that the first patient has been enrolled in the EMIT-AF/VTE (Edoxaban Management In diagnostic and Therapeutic procedures) study. This registry will collect real-world clinical data on the use of once-daily LIXIANA® (edoxaban) with regard to diagnostic and interventional procedures in patients with non-valvular atrial fibrillation (NVAF) or venous thromboembolism (VTE). Limited information is currently available regarding the use of edoxaban in patients undergoing medical procedures. Patients who are treated with non-vitamin K antagonist oral anticoagulants (NOACs), such as edoxaban, undergo diagnostic and therapeutic procedures at a rate of 10% a year, and if the surgical interventions carry a bleeding risk, NOAC treatment must be temporarily discontinued. The EMIT-AF/VTE study will provide further insight into the use of edoxaban in patients undergoing diagnostic and therapeutic procedures. Patients will be enrolled from primary and secondary care settings, as well as other specialty settings. The primary objective of the study is to document the peri-procedural management of edoxaban and collect data on safety and other outcomes in these patients. The primary safety outcome is the rate of major bleeding (within 30 days post intervention) using the ISTH definition. The EMIT-AF/VTE registry will comprise approximately 2,000 patients over the next two and a half years. Data will be collected from patients treated with edoxaban for 2,000 planned or unplanned procedures across 500 sites, including hospitals and office-based sites, in Belgium, France, Germany, Italy, The Netherlands, Spain, and the UK. Daiichi Sankyo is also reviewing options to expand the EMIT-AF/VTE registry to clinical sites beyond Europe.

Similar Private Companies By Industry

Company Name Region
3B Pharmaceuticals GmbH Europe
Accelsiors Group International Europe
Aenova Group GmbH Europe
Aenova Holding GmbH Europe
AiCuris GmbH & Co. KG Europe

Recent Private Companies Transactions

Type
Date
Target
No transactions available in the past 12 months.
 

The information and data displayed in this profile are created and managed by S&P Global Market Intelligence, a division of S&P Global. Bloomberg.com does not create or control the content. For inquiries, please contact S&P Global Market Intelligence directly by clicking here.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Bertelsmann AG Europe
The Advertising Council, Inc. United States
Rush University United States

Sponsored Financial Commentaries

Sponsored Links

Request Profile Update

Only a company representative may request an update for the company profile. Documentation will be required.

To contact Daiichi Sankyo Europe GmbH, please visit www.daiichi-sankyo.eu. Company data is provided by S&P Global Market Intelligence. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.